The Pharmacogenetics of Nicotine Addiction Treatment (PNAT) Consortium was formed in 2005 to identify the role of pharmacokinetic and pharmacodynamic gene variation on nicotine dependence and metabolism phenotypes, with a focus on smoking cessation and medication response, and to generate the evidence base to optimize the use of pharmacotherapies for smoking cessation. In this analysis, we conduct analyses of the association of nAChR candidate gene variation with abstinence at EOT and at 6MO after the quit date in 2,633 treatment-seeking smokers enrolled in eight RCTs of smoking cessation. We performed analyses by PG, including predictor SNP regression, sensitivity, mediation, and receiver operator curve analyses. We performed these analyses to address the questions: a) are any of the four nAChR SNPs of a priori interest significantly associated with abstinence in smokers grouped by pharmacotherapy, and b) how do the results help our understanding of the pharmacogenetic mechanisms that operate in smoking cessation?
